91 related articles for article (PubMed ID: 26563635)
1. Metabonomic diagnosis of bladder cancer: what are the advantages and considerations?
Hong Y; Esuvaranathan K; Pasikanti KK; Yong Chan EC
Bioanalysis; 2015 Nov; 7(21):2727-9. PubMed ID: 26563635
[No Abstract] [Full Text] [Related]
2. Metabonomic profiling of bladder cancer.
Chan EC; Pasikanti KK; Hong Y; Ho PC; Mahendran R; Raman Nee Mani L; Chiong E; Esuvaranathan K
J Proteome Res; 2015 Feb; 14(2):587-602. PubMed ID: 25388527
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics and bladder cancer.
Hyndman ME; Mullins JK; Bivalacqua TJ
Urol Oncol; 2011; 29(5):558-61. PubMed ID: 21930087
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive urinary metabonomic diagnosis of human bladder cancer.
Pasikanti KK; Esuvaranathan K; Ho PC; Mahendran R; Kamaraj R; Wu QH; Chiong E; Chan EC
J Proteome Res; 2010 Jun; 9(6):2988-95. PubMed ID: 20337499
[TBL] [Abstract][Full Text] [Related]
5. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry.
Issaq HJ; Nativ O; Waybright T; Luke B; Veenstra TD; Issaq EJ; Kravstov A; Mullerad M
J Urol; 2008 Jun; 179(6):2422-6. PubMed ID: 18433783
[TBL] [Abstract][Full Text] [Related]
6. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C
J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504
[TBL] [Abstract][Full Text] [Related]
7. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
8. UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry.
Zhao YY; Cheng XL; Vaziri ND; Liu S; Lin RC
Clin Biochem; 2014 Oct; 47(15):16-26. PubMed ID: 25087975
[TBL] [Abstract][Full Text] [Related]
9. Counting missing values in a metabolite-intensity data set for measuring the analytical performance of a metabolomics platform.
Huan T; Li L
Anal Chem; 2015 Jan; 87(2):1306-13. PubMed ID: 25496403
[TBL] [Abstract][Full Text] [Related]
10. Tissue microarrays in clinical urology--technical considerations.
Kramer MW; Merseburger AS; Hennenlotter J; Kuczyk M
Scand J Urol Nephrol; 2007; 41(6):478-84. PubMed ID: 17907050
[TBL] [Abstract][Full Text] [Related]
11. Metabolic footprinting of tumorigenic and nontumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry.
Pasikanti KK; Norasmara J; Cai S; Mahendran R; Esuvaranathan K; Ho PC; Chan EC
Anal Bioanal Chem; 2010 Oct; 398(3):1285-93. PubMed ID: 20686754
[TBL] [Abstract][Full Text] [Related]
12. Tryptophan urinary bladder absorption and bladder cancer.
Flanagan MJ; Ekbal S; Coogan PS; Kalin G; Hass GM
Invest Urol; 1975 Jul; 13(1):17-9. PubMed ID: 1140915
[TBL] [Abstract][Full Text] [Related]
13. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients.
Chen CL; Lai YF; Tang P; Chien KY; Yu JS; Tsai CH; Chen HW; Wu CC; Chung T; Hsu CW; Chen CD; Chang YS; Chang PL; Chen YT
J Proteome Res; 2012 Dec; 11(12):5611-29. PubMed ID: 23082778
[TBL] [Abstract][Full Text] [Related]
14. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry.
Pasikanti KK; Esuvaranathan K; Hong Y; Ho PC; Mahendran R; Raman Nee Mani L; Chiong E; Chan EC
J Proteome Res; 2013 Sep; 12(9):3865-73. PubMed ID: 23885889
[TBL] [Abstract][Full Text] [Related]
15. Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer.
Lin L; Yu Q; Yan X; Hang W; Zheng J; Xing J; Huang B
Analyst; 2010 Nov; 135(11):2970-8. PubMed ID: 20856980
[TBL] [Abstract][Full Text] [Related]
16. Haematoporphyrins in the diagnosis and treatment of carcinoma of the bladder.
Kelly JF
Proc R Soc Med; 1975 Aug; 68(8):527-8. PubMed ID: 1202494
[TBL] [Abstract][Full Text] [Related]
17. Urinary metabonomics of stomach cancer assessed by rapid resolution liquid chromatography/time-of-fight mass spectrometry.
Zhang Y; Ren H; Jiang Y; Gao YF; Liu SY
Chin Med J (Engl); 2013; 126(10):1930-3. PubMed ID: 23673112
[TBL] [Abstract][Full Text] [Related]
18. Evolution of bladder cancer in man.
Cooper EH; Levi PE; Anderson CK; Williams RE
Proc R Soc Med; 1969 Aug; 62(8):865-6. PubMed ID: 5810324
[No Abstract] [Full Text] [Related]
19. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers.
Chen YT; Chen HW; Domanski D; Smith DS; Liang KH; Wu CC; Chen CL; Chung T; Chen MC; Chang YS; Parker CE; Borchers CH; Yu JS
J Proteomics; 2012 Jun; 75(12):3529-45. PubMed ID: 22236518
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and differential diagnosis of malignant glandular and glandular-like lesions of the urinary bladder].
Cheng L; Huang WB; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):57-61. PubMed ID: 23611280
[No Abstract] [Full Text] [Related]
[Next] [New Search]
